A randomised, double-blind, placebo-controlled, factorial-design trial to assess the effect of aspirin and fish oil (omega-3 fatty acids) in the prevention of early thrombosis in arterio-venous fistulae in patients with Stage IV or V chronic kidney disease requiring haemodialysis.

Trial Profile

A randomised, double-blind, placebo-controlled, factorial-design trial to assess the effect of aspirin and fish oil (omega-3 fatty acids) in the prevention of early thrombosis in arterio-venous fistulae in patients with Stage IV or V chronic kidney disease requiring haemodialysis.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Aspirin (Primary) ; Omega 3 fatty acids (Primary)
  • Indications Thrombosis
  • Focus Therapeutic Use
  • Acronyms FAVOURED
  • Most Recent Events

    • 02 Apr 2015 Status changed from recruiting to completed as per Australian New Zealand Clinical Trials Registry record .
    • 31 May 2012 Additional lead trial centre added as reported by United Kingdom Clinical Research Network.
    • 22 Mar 2012 Planned end date (Mar 2014) added as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top